Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding trial of LYT-100 (deupirfenidone) in idiopathic pulmonary fibrosis
2021-006820-41Phase 2Active
- Sponsor
- PureTech Health
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deupirfenidone in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by PureTech Health. Primary endpoint: Rate of decline in FVC (mL) over Part A (26 weeks). Started Sep 2022; status: active.
02
Drugs
deupirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2021-006820-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006820-41.